Deadline: 03-Nov-2025
The Breakthrough T1D has launched a new Request for Applications (RFA) aimed at advancing understanding of how insulin dose impacts outcomes for people living with type 1 diabetes (T1D).
Since individuals with T1D depend on lifelong insulin therapy to manage glucose control, prevent diabetic ketoacidosis (DKA), and reduce long-term complications, this initiative seeks to explore whether reducing insulin doses—without compromising safety—can offer added benefits to patients.
The program invites proposals that investigate the relationship between insulin dose and both acute and long-term health outcomes in T1D. Potential studies could analyze existing data from registries, clinical trials, electronic health records, or medical claims to better understand dose-related outcomes. Retrospective and prospective observational studies, as well as mechanistic clinical trials, are also encouraged. By contrast, the initiative will not fund studies in preclinical models, biomarker discovery unrelated to insulin dosing, development of new insulins or delivery systems, or research into unrelated disease-modifying therapies.
Funding for this opportunity is set at up to $750,000 over a maximum of two years, supporting both SRA and IDDP applications. Eligible applicants include domestic and foreign non-profit and public organizations, such as universities, hospitals, and laboratories, as well as units of state or local governments and certain federal agencies. For-profit entities or industry-academic collaborations may also apply, though they will be required to submit additional details if invited to the full application stage.
This RFA is open to qualified researchers holding an M.D., D.O., D.M.D., D.V.M., Ph.D., or equivalent, with a faculty position at a research institution. Breakthrough T1D emphasizes inclusivity and strongly encourages applications from women, people with disabilities, and members of underrepresented minority groups in the sciences.
By funding innovative studies on insulin dose and dose reduction, Breakthrough T1D aims to generate insights that could shape more effective, safer, and individualized treatment approaches for people managing type 1 diabetes.
For more information, visit Breakthrough T1D.
